Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $9.35 in the last session, up 2.86% from day before closing price of $9.09. In other words, the price has increased by $2.86 from its previous closing price. On the day, 0.91 million shares were traded. LXEO stock price reached its highest trading level at $9.445 during the session, while it also had its lowest trading level at $9.11.
Ratios:
We take a closer look at LXEO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.40 and its Current Ratio is at 7.40. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on November 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $19.
On October 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $30.
On July 31, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $20.Oppenheimer initiated its Outperform rating on July 31, 2025, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 18 ’25 when Townsend Richard Nolan sold 1,127 shares for $9.27 per share. The transaction valued at 10,447 led to the insider holds 240,991 shares of the business.
Adler Eric sold 615 shares of LXEO for $5,701 on Nov 18 ’25. The Chief Medical Officer now owns 72,646 shares after completing the transaction at $9.27 per share. On Nov 18 ’25, another insider, See Tai Sandi, who serves as the Chief Development Officer of the company, sold 386 shares for $9.27 each. As a result, the insider received 3,578 and left with 65,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 682431552 and an Enterprise Value of 568124480.
Stock Price History:
The Beta on a monthly basis for LXEO is 1.83, which has changed by 0.12786496 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $10.38, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 7.45%, while the 200-Day Moving Average is calculated to be 84.35%.
Shares Statistics:
According to the various share statistics, LXEO traded on average about 1.25M shares per day over the past 3-months and 1010050 shares per day over the past 10 days. A total of 72.99M shares are outstanding, with a floating share count of 60.28M. Insiders hold about 17.40% of the company’s shares, while institutions hold 75.64% stake in the company. Shares short for LXEO as of 1763078400 were 5636938 with a Short Ratio of 4.52, compared to 1760486400 on 7315216. Therefore, it implies a Short% of Shares Outstanding of 5636938 and a Short% of Float of 8.2600005.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.31 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.68 and -$2.26 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$1.53, with 8.0 analysts recommending between -$1.11 and -$2.36.
